Biotech sits at the meeting point of human health and durable structural tailwinds, ageing populations, scientific breakthroughs, and rising healthcare spend. Scott's clients access biotech selectively, through specialist managers and diversified vehicles, sized as a measured allocation within a broader plan.
Equity and venture exposure to companies developing therapeutics, diagnostics, genomics and platform technologies in human health. The opportunity set spans listed biotech, late-stage private companies preparing for trial readouts or commercial launch, and earlier-stage ventures backing breakthrough science.
Therapeutic markets are large, durable and growing. Successful biotech exits, clinical milestones, strategic acquisitions, IPOs, can return multiples of capital. Scott's role is to size biotech as a small, measured allocation within a broader plan, not a concentrated bet.
Through specialist healthcare-focused VC and growth funds on BGW's APL, diversified late-stage private-shares strategies that include biotech alongside other innovation themes, and direct allocations sourced through Boston Global Group's relationships in the medical-research community.
Biotech is high risk by nature, binary clinical and regulatory outcomes, long timelines, and significant single-company concentration risk. Approved exposure is risk capital only, sized to the client's overall plan, and held in diversified vehicles wherever possible.
Scott will tell you straight. Whether it earns its place, how much would make sense, and how it fits alongside what you already hold.
Book a Consultation